DEF 14A: Mangoceuticals, Inc. Sets Date for Annual Stockholders Meeting, Proposes Key Governance and Financial Approvals

Mangoceuticals, Inc. will hold its annual meeting on June 17, 2024, seeking stockholder approval for director elections, stock issuances, auditor ratification, and potential meeting adjournment.

Summary

• Mangoceuticals, Inc. is holding its Annual Meeting of Stockholders on June 17, 2024, to vote on several key proposals.
• The proposals include the election of four directors, approval of common stock issuances related to Series B and C Convertible Preferred Stock and an Equity Purchase Agreement (ELOC), ratification of the appointment of Turner, Stone & Company, L.L.P. as independent auditors, and approval to adjourn the meeting if necessary to solicit additional proxies.
• The board recommends voting in favor of all nominees and proposals.
• Stockholders of record as of May 6, 2024, are entitled to vote, with 24,819,500 shares of common stock outstanding.
• The company is a Texas corporation formed on October 7, 2021, focused on men's wellness telemedicine services and products.
• The company has not yet generated revenues sufficient to support its operations.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily focused on outlining proposals for the annual meeting. While it highlights potential benefits of the proposals, it also acknowledges potential risks and dilutive effects. The company's limited operating history and dependence on related party transactions temper the overall sentiment.

Positives

• The company is taking steps to comply with Nasdaq listing rules regarding stock issuances.
• The board is actively engaged in corporate governance, including establishing committees and policies.
• Stockholders have multiple options for voting, including in person, via the internet, by telephone, or by mail.
• The company has adopted a Clawback Policy for the recovery of erroneously awarded incentive-based compensation.
• The company has adopted a Whistleblower Protection Policy.

Negatives

• The company has not yet generated revenues sufficient to support its operations.
• The company is seeking approval for significant stock issuances, which could dilute existing stockholders' ownership.
• The company is dependent on related party transactions, including a Master Services Agreement with Epiq Scripts, LLC, which is partially owned by the CEO.
• The company has a history of related party loans and advances.
• The company has had instances of delinquent Section 16(a) reports by executive officers.

Risks

• Failure to obtain stockholder approval for the proposed stock issuances could jeopardize the company's ability to execute its business plan and raise capital.
• The company's reliance on related party transactions could raise concerns about conflicts of interest and the fairness of terms.
• The potential for significant dilution from stock issuances could negatively impact the market price of the company's common stock.
• The company's dependence on Epiq Scripts for pharmacy services exposes it to risks related to Epiq Scripts' licensing and operations.
• The company's limited operating history and lack of significant revenue generation pose challenges to its long-term viability.

Future Outlook

The company intends to utilize the Patents by commencing research, development, clinical trial studies and efficacy testing on a variety of oral applications including, but not limited to, an oral dissolvable tablet (ODT), lozenge, toothpaste and/or mouthwash.

Management Comments

• Our Board of Directors encourages your participation in Mangoceuticals, Inc.s electoral process and, to that end, solicits your proxy with respect to the matters described in the Notice of Meeting and the proxy statement.
• We look forward to seeing you on Monday, June 17, 2024.
• Your vote and participation in our governance is very important to us.

Industry Context

The document notes that mens wellness telemedicine services and products are a growing sector, particularly in areas like erectile dysfunction and hair growth.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or competitors.
• However, it mentions that the company has identified mens wellness telemedicine services and products as a growing sector.
• The document does not provide specific comparisons to industry standards or competitors.

Related Party Transactions

• The company has engaged in multiple related party transactions, including issuances of securities, loans, and service agreements with entities affiliated with officers and directors.
• The company has a Master Services Agreement with Epiq Scripts, LLC, which is partially owned by the CEO, for pharmacy and related services.
• The company has entered into Consulting Agreements with consultants who are also employees of Epiq Scripts.

Stakeholder Impact

• Approval of the proposals could enable the company to raise capital and execute its business plan, potentially benefiting stockholders.
• However, the proposed stock issuances could dilute existing stockholders' ownership and negatively impact the market price of the company's common stock.
• The company's reliance on related party transactions could raise concerns about conflicts of interest and the fairness of terms for stakeholders.

Next Steps

• Stockholders to vote on the proposals at the Annual Meeting on June 17, 2024.
• The company to file a resale registration statement with the SEC to register the shares of the Companys common stock issuable upon conversion of all shares of Series B Preferred Stock which may be sold at the Initial Closing, Second Closing and Third Closing (and if such Option Closing has occurred as of such date, the Option Conversion Shares), shares of common stock issuable in lieu of cash dividends which could accrue on the Series B preferred Stock for a period of two years, and the Warrant Shares, within 30 days of the Closing Date.
• The company to file a resale registration statement with the SEC to register all common stock underlying the Advance Shares, and the Commitment Shares, within 30 days of the Initial Closing Date.

Key Dates

Keywords

proxy statement, annual meeting, stockholders, directors, stock issuance, Nasdaq, auditors, executive compensation, related party transactions, corporate governance, Series B Preferred Stock, Series C Preferred Stock, Equity Purchase Agreement, ELOC, Turner Stone & Company